Crispr Therapeutics AG

Stock Chart, Company Information, and Scan Results

$68.21(as of Jul 21, 11:07 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Crispr Therapeutics AG Company Information, Fundamentals, and Technical Indicators

Stock Price$68.21
Ticker SymbolCRSP
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees393
CountyUSA
Market Cap$5,624.9M
EBIDTA-455.2M
10-Day Moving Average56.64
P/E Ratio-14.51
20-Day Moving Average52.29
Forward P/E Ratio23.36
50-Day Moving Average44.13
Earnings per Share-4.49
200-Day Moving Average43.65
Profit Margin-15,722.08%
RSI75.56
Shares Outstanding86.4M
ATR3.48
52-Week High66.49
Volume10,165,913
52-Week Low30.04
Most Recent Support Level52.33
Book Value1,829.2M
Most Recent Resistance Level56.87
P/B Ratio3.06
Upper Keltner60.12
P/S Ratio151.34
Lower Keltner44.46
Debt-to-Equity Ratio60.12
Next Earnings Date08/11/2025
Cash Surplus115.7M
Next Ex-Dividend DateUnknown

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease (SCD), and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting cluster of differentiation 19 (CD19) and CTX131 targeting CD70 for oncology and autoimmune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and CTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Crispr Therapeutics AG In Our Stock Scanner

example chart graphic
Date: Jul 21, 2025Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
example chart graphic
Date: Jul 21, 2025Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Date: Jul 21, 2025Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 21, 2025Scan Name: 52-Week HighScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 21, 2025Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Date: Jul 21, 2025Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---
example chart graphic
Date: Jul 21, 2025Scan Name: Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Date: Jul 21, 2025Scan Name: Golden CrossScan Type: Stock Indicator Scans
As of ---
example chart graphic
Date: Jul 21, 2025Scan Name: Stocks with Unusual VolumeScan Type: Stock Indicator Scans
As of ---
example chart graphic
Date: Jul 21, 2025Scan Name: Momentum StocksScan Type: Stock Indicator Scans
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.